Invesco Dynamic Biotechnology & Genome ETF

Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

Цена последней сделки 71.02
Код ценной бумаги PBE
Полное наименование Invesco Dynamic Biotechnology & Genome ETF
Объем 349120000000
Изм за день, % -0.05
Комиссия 0.58
Дата основания Jun 23. 2005
Ссылка ссылка
Тип актива Equity
Индекс Dynamic Biotechnology & Genome Intellidex Index
Регион North America
Средний P/E 51.9
Дивиденды 0.04
5 летняя доходность 82.82
3 летняя доходность 38.30
Годовая доходность 39.53
Бета 1.08
Валюта usd
Топ 10 эмитентов, % 48.40
Количество компаний 31

Топ эмитентов

Эмитент Доля, % P/BV P/S P/E EV/Ebitda
Fulgent Genetics, Inc. 6.38 12.93 18.64 48.48 39.73
Alexion 5.08 2.86 5.49 55.76 10.45
Biogen 4.63 3.88 3.09 11 9.16
Vertex 4.08 6.35 8.89 20.63 16.44
Intellia Therapeutics, Inc. 4.04 7.79 72.37 -29
Seagen 3.89 7.97 12.8 45.61 38.74
CareDx, Inc 3.4 14.85 22.48 -250.72
Dicerna Pharmaceuticals, Inc. 2.92 16.22 13.47 -13.9
Emergent BioSolutions Inc. 2.85 3.16 2.95 15.21 8.64

Похожие ETF

Описание Invesco Dynamic Biotechnology & Genome ETF

This ETF offers exposure to the biotech sub-sector of the U.S. health care industry, serving up access to a group of stocks that can thrive on technological breakthroughs and increased investment in medical processes. PBE is part of the suite of Dynamic ETFs from PowerShares, using quant-based screening to identify component companies that may be poised for outperformance relative to a broad-based universe. As such, the portfolio of this ETF is considerably more limited than IBB, which includes more than 100 individual names. That feature can be particularly important in the biotech space, where company-specific developments can send a single stock soaring. PBE does a nice job of spreading exposure evenly across the portfolio components, which include a balance of large caps, mid caps, and small cap stocks. IBB and FBT are other ETF options for biotech exposure; those considering this sector should take a close look at depth of exposure and weighing methodology, as these factors can have a major impact on the risk and return profiles achieved. The expense differentials are also worth noting; PBE is a bit more expensive than the iShares alternative.